Clarissa Parker to Kaplan-Meier Estimate
This is a "connection" page, showing publications Clarissa Parker has written about Kaplan-Meier Estimate.
Connection Strength
0.068
-
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9.
Score: 0.068